Abstract:BackgroundAbnormal expression of microRNAs (miRNAs) is related to human carcinogenesis. Although previous studies have shown that miR-503 expression in gastric cancer (GC) is downregulated, however, the underlying molecular mechanism for miR-503 involved in gastric cancer development is still largely unknown.MethodsThe relative expression of miR-503 in GC tissues and adjacent normal tissues was examined using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) analyses. In vitro, cell proliferation and invasion were evaluated by using CCK8, cell colony and transwell invasion assays. In vivo, xenograft tumor model was constructed to assess miR-503 expression whether affects tumor growth or not. Luciferase reporter assay, qRT-PCR and western blot assay were used to demonstrate HMGA2 is a target of miR-503.ResultsWe demonstrated that miR-503 expression was significantly downregulated in GC tissues and cell lines compared to adjacent normal tissues and normal gastric mucosa cell lines, respectively. Lower miR-503 expression associated with tumor size, lymph node metastasis, and predicted a poor overall survival (OS) time in GC patients. Subsequently, in vitro, gain-function and loss-function assays confirmed that miR-503 overexpression significantly suppressed GC cell proliferation, colony formation and cell invasion, while decreased miR-503 expression had an adverse effect in GC cells. Furthermore, we found that miR-503 specifically targeted the 3′-UTR regions of HMGA2 mRNA and suppressed its protein expression. Overexpression of HMGA2 could reverse the miR-503 mediated inhibition of GC cell proliferation and invasion. In vivo, miR-503 overexpression dramatically reduced tumor growth. Moreover, we demonstrated that miR-503 suppressed WNT/β-catenin signaling by elevating GSK-3β and p-β-catenin expression, but decreased p-GSK-3β and β-catenin expression in GC cells.ConclusionThese results provide that miR-503 expression acts as a predictor for GC prognosis and may have a potential application in GC therapy.

miR-137 effects on gastric carcinogenesis are mediated by targeting Cox-2-activated PI3K/AKT signaling pathway.

Epigenetic silencing of miR 137 in gastric cancer

miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2.

Mir-137 Plays Tumor Suppressor Roles in Gastric Cancer Cell Lines by Targeting KLF12 and MYO1C

Mir-129-5p Attenuates Cell Proliferation and Epithelial Mesenchymal Transition Via HMGB1 in Gastric Cancer

MiR-181d Inhibits Cell Proliferation and Metastasis Through PI3K/AKT Pathway in Gastric Cancer.

MiR-375 Frequently Downregulated in Gastric Cancer Inhibits Cell Proliferation by Targeting JAK2

Mir-1297 Regulates The Growth, Migration And Invasion Of Colorectal Cancer Cells By Targeting Cyclo-Oxygenase-2

MiR-129-5p Induces Cell Cycle Arrest Through Modulating HOXC10/Cyclin D1 to Inhibit Gastric Cancer Progression.

miR-502-5p affects gastric cancer progression by targeting PD-L1

miR-135b-5p promotes gastric carcinogenesis by targeting CLIP4-mediated JAK2/STAT3 signal pathway

MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation.

Mir193b Promotes Apoptosis of Gastric Cancer Cells Via Directly Mediating the Akt Pathway

MiRNA-766-3p inhibits gastric cancer via targeting COL1A1 and regulating PI3K/AKT signaling pathway

MiR-139-5p inhibits the proliferation of gastric cancer cells by targeting Regulation of Nuclear Pre-mRNA Domain Containing 1B

MiR-152-5p as a microRNA passenger strand special functions in human gastric cancer cells

miR-133b Suppresses Invasion and Migration of Gastric Cancer Cells via the COL1A1/TGF-β Axis

MicroRNA-1 Acts As a Tumor Suppressor Microrna by Inhibiting Angiogenesis-Related Growth Factors in Human Gastric Cancer

miR-335-5p suppresses gastric cancer progression by targeting MAPK10

MiR-503 suppresses cell proliferation and invasion of gastric cancer by targeting HMGA2 and inactivating WNT signaling pathway

Nuclear magnetic resonance studies of the interaction of trans-cnnamate with alpha-chymotrypsin.